Drugs like Herceptin have pioneered new--but limited--approaches to HER2-positive cancer that can help about 20% of all breast cancer patients. Now a team of investigators at the Mayo Clinic says they may have found the key to taking this approach one big step forward, with implications for a range of cancers.
In the world of Alzheimer's drug research, there's no lack of certainty among leading researchers. There's just no consensus on what causes the disease or how to treat it.
The Mayo Clinic has found that gadolinium-based contrast agents used in MRI exams leave deposits in the brain. The researchers said that there is no evidence that the gadolinium deposits are harmful to patients and continues to recommend the use of gadolinium-based contrast agents as appropriate.
Investigators have begun testing new drugs that can specifically hunt down and eliminate senescent cells in mice, opening the door to what they say could be a new class of therapeutics that promise to one day slow down the human aging process.
The Mayo Clinic and Gentag are partnering to develop next-generation, wireless, disposable patch sensors to enable researchers to track patient movements in order to better address conditions such as diabetes and obesity.
As the med tech industry homes in on innovative technologies that can speed up diagnosis for strokes, healthcare providers are harnessing next-generation products to improve outcomes for patients.
Allen Zderad lost his vision, but due to a bionic eye implant from a clinical trial, he regained the ability to see human forms and outlines of objects. The implant sends light wave signals to the optic nerve, compensating for a damaged retina.
Yet another next-generation sequencing startup has disclosed that it's won financing. Lifecode, formerly known as Silicon Valley Biosystems, has garnered a $20.5 million Series A round from investors including Sequoia Capital, The Mayo Clinic and Mayo Ventures.
Minnesota's Mayo Clinic is suing one of its former top executives for misappropriation of trade secrets as part of a plan to work for competitor Quest Diagnostics following a false retirement.
Researchers may have found the key to destroying the amyloid-β clumps long associated with Alzheimer's disease, which could spur new approaches to drug discovery in a field that has seen more than its share of failures.